EcoDrugPlus

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSCHAG00000012174
Gene Symbol: CFTR
3 Cross references
217 Possible Orthologues:

D(1) Dopamine Receptor-Like

Ensembl ID : ENSCHAG00000002951
Gene Symbol: LOC105909153
3 Cross references
200 Possible Orthologues:

D(2)-Like Dopamine Receptor

Ensembl ID : ENSCHAG00000003102
Gene Symbol: LOC105895334
3 Cross references
206 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSCHAG00000015979
Gene Symbol: DNMT1
3 Cross references
212 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSCHAG00000023109
Gene Symbol: TOP1
1 Cross references
201 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSCHAG00000011438
Gene Symbol: TOP2A
3 Cross references
207 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSCHAG00000005470
Gene Symbol: TOP2B
1 Cross references
209 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSCHAG00000018324
Gene Symbol: EML4
1 Cross references
212 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSCHAG00000008894
Gene Symbol: EPHA3
3 Cross references
216 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSCHAG00000024022
Gene Symbol: F2RL3
3 Cross references
188 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSCHAG00000024030
Gene Symbol: F2RL3
3 Cross references
188 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSCHAG00000024032
Gene Symbol: F2RL3
1 Cross references
188 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).